Glenmark, in a short span, has been able to build an admirable pipeline of 13 molecules; four of which are in clinical development and the other nine are at various stages of pre-clinical development and discovery.

 
   
 
RESEARCH FOCUS
NCE RESEARCH
 Metabolic Disorders
  • Diabetes (Type II)
• Obesity
 Inflammation
  • Asthma/COPD
 Pain
  • Neuropathic Pain
  • Inflammatory Pain
 
BIOLOGICS
 Oncology and Inflammation
   
     
 NCE Research – In Mumbai, India
 

• Focused capability building over
  5 years; spend ~5% of revenues

• Eminent scientific advisory board

• 5 leads
       •     3 in Ph II
      •     1 in Ph I  
      •     1 entering in Ph I

 
 Target: 1-2 NCEs into clinics
 every year
 
 Biologics Research in Switzerland
  • Lab commissioned, 55+ scientists

• Further expand Biologics capabilities     through in-licensing and potential    acquisitions

• 5 lead - 1 late preclinical,
  1 preclinical,  3 lead generation
  / optimization stage
 
 Target : First lead in to clinics
 in FY 2009
   
Progress on NCE Pipeline:

 Compound

 Target

 Primary  Indications
 Status

 GRC 3886
 (Oglemilast)
 PDE-4
 Asthma, COPD
 Phase II
 GRC 8200
 DPP-IV
 Diabetes ( Type II )
 Phase II
 GRC 6211
 VR-1
 Osteoarthritis,
 Dental Pain,  Incontinence,  Neuropathic  Pain
 Phase II
 GRC 4039  PDE 4  Rheumatoid  Arthritis,  Inflammation,
 Multiple Sclerosis

 Ph I –Expects to complete by October,2008

Ph II
Initiation by January 2009
 GRC 10693  CB 2  Neuropathic Pain,  Osteoarthritis and

 other Inflammatory  Pain		  Ph I to start by
 Q3 FY09
 GRC 9332  SCD 1  Obesity,
 Dyslipidemia,
 Metabolic Disorders

  Pre clinical,to
 enter Phase I
 Q4 FY 09
 GRC 17173
 TRPV3  Osteoarthritis,
 Neuropathic Pain,
 Dental Pain

  Pre clinical, to
 enter Phase I
 Q3 FY 09
   
  Biologics Pipeline:

 Lead

 Target

 Indication
 Stage
 Status

 GBR 500
 SAMI
 Acute multiple  sclerosis;  Inflammatory  Disorders
 PH 1 expects to complete in FY09
 • Broad inflammatory agent    with a novel mechanism of    action, being developed    initially to treat acute multiple    sclerosis, for which no    treatment is approved
   at present
 GBR 600
 VWF
 Acute stroke /  Coronary Syndrome;  Thrombosis  Cardiovascular  disorders
 PH 1 to start  by Q4 FY 2009
 • Anti thrombolytic humanized    monoclonal antibody which    is being developed initially to    treat acute stroke